glp-1 fda approved for weight loss New Pill Foundayo (Orforglipron) Gets Approval Obesity Eli Lilly's Foundayo GLP-1 Weight

The initiation of an SGLT2 inhibitor or a GLP-1 receptor agonist compared with a DPP-IV inhibitor was associated with lower CV events and death without increasing the overall incidence rate of severe safety outcomes, regardless of frailty status, Elisabetta Patorno, MD, DrPH , associate professor of medicine at Harvard Medical School and associate epidemiologist in the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Womens Hospital, and colleagues wrote

[2] Beyond pigmentation, glutathione's antioxidant properties protect skin cells from UV-induced oxidative damage and support collagen integrity

l , cellular respiration

Ilic S, Drmic D, Franjic S, Kolenc D, Coric M, Brcic L, Klicek R, Radic B, Sever M, Djuzel V, Filipovic M

doi: 10.1111/and.2016.48.issue-7 79 AppletonJ

Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults